A phase 3 clinical trial published in May 2026 evaluated AD109, an oral combination that remains investigational, in adults with obstructive sleep apnea who could not tolerate or declined positive airway pressure therapy. The results showed a greater reduction in the apnea–hypopnea index compared with placebo, but do not represent approval of the medication or a recommendation to replace treatments already prescribed.
How the study was conducted
SynAIRgy was a randomized, double-blind, placebo-controlled trial conducted at 69 centers. It included 646 adults with mild to severe obstructive sleep apnea. The main follow-up period lasted 26 weeks. The study evaluated a combination of aroxybutynin and atomoxetine, developed to act on the neuromuscular function of the upper airway during sleep.
What the researchers observed
At week 26, the modeled reduction in the apnea–hypopnea index was 44.1% in the AD109 group and 17.6% in the placebo group; the mean difference between the groups was 4 events per hour. Improvements in measures of oxygenation were also observed. The study found no statistically significant difference between the groups in the participant-reported fatigue outcome, an important point to avoid turning a physiological result into a promise of improvement in all symptoms.
Adverse events led to treatment discontinuation in 21.2% of participants who received AD109, compared with 3.1% in the placebo group. Among the most commonly reported events were dry mouth, nausea, insomnia, and difficulty urinating. These data need to be considered alongside the efficacy results.
What the results do not mean
The trial studied a specific group: people with apnea who did not use or did not accept positive airway pressure. It does not demonstrate that all patients should switch treatments, nor does it establish long-term safety and benefit. The choice between CPAP, an oral appliance, surgery, or other options depends on individual assessment; a prescribed treatment should not be stopped on the basis of a news report.
The American Thoracic Society reported that the manufacturer had submitted an application for review to the FDA in the United States. A regulatory application is not an approval and does not confirm the product’s availability or registration in Brazil. The situation in Brazil should be checked through official channels before making any statement about local access.
Funding and interpretation
The article states that the study was funded by Apnimed, the company responsible for developing AD109. Three authors were employees and shareholders of the company, and medical writing support was funded by the company. Transparency about these ties is part of critically appraising the results; it does not automatically invalidate the study, but should be taken into account.
For those with frequent snoring, observed pauses in breathing, or daytime sleepiness, the next step is not to seek an experimental medication: it is to speak with a professional to assess the concern and decide whether a sleep study is indicated.
Sources
- Strollo et al. SynAIRgy, phase 3 randomized trial. American Journal of Respiratory and Critical Care Medicine, 2026.
- American Thoracic Society: statement on the results and regulatory status.
Journalistic and educational content. It does not replace medical assessment and does not constitute a treatment recommendation.